首页> 外文期刊>National Journal of Laboratory Medicine >Expression of Ki67 as a Prognostic Marker in Invasive Breast Carcinoma
【24h】

Expression of Ki67 as a Prognostic Marker in Invasive Breast Carcinoma

机译:Ki67表达作为浸润性乳腺癌的预后标志物。

获取原文
       

摘要

Introduction: Breast cancer is the most common cancer in women of developed countries. It accounts for 16% and 22.9% of cancers and invasive cancers, respectively. About 18.2% of deaths related to cancer amongst men and women have been attributed to breast cancer. Every year, more than 10,000 incipient breast cancer patients reckon to be diagnosed in India.Aim: To evaluate the role of Ki67 as a predictive biomarker in invasive breast cancer patients and to study its correlation with various molecular subtypes of breast cancer.Materials and Methods: A cross-sectional and descriptive study, of 100 cases of breast carcinoma coming to Histopathology section in Department of Pathology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, India, was carried out over a period of one year, from 2013 to 2014. Patients were randomly selected for the study.Results: Sixty nine patients showed high proliferating index of Ki67 (>30%), followed by 20% patients that showed low proliferating index (≤15%) and 11% patients showed intermediate proliferating index (16-30%). Maximum patients were of Luminal A subtype, of which 50% showed high proliferating index. In the Luminal B subtype, 64% patients showed high proliferating index and in the Her-2 subtype, 73.9% showed high proliferating index. Of Triple Negative Breast Cancer (TNBC) subtype 86.3% showed high proliferating index. Majority of patients were of IDC (n=94). Out of these, 64(68%) patients showed high proliferating index for Ki67 immunostaining. Out of 5 patients of ILC, 3 (60%) showed high proliferating index for Ki67 immunostaining. One case of mucinous carcinoma showed low proliferating index for Ki67 immunostaining.Conclusion: High proliferating index tumours were mostly large in size. We could not find any correlation with various molecular subtypes of breast carcinoma. Though, not statistically significant, we observed that TNBC were most aggressive and showed highest rate of proliferation and Ki67 expression.High levels of Ki67 were associated with TNBC, Her2eu and Luminal B while low and medium levels with Luminal A subtype. Ki67 immunostaining can be used as an important biomarker for proliferation.
机译:简介:乳腺癌是发达国家女性中最常见的癌症。它分别占癌症和浸润性癌症的16%和22.9%。在男女中,与癌症有关的死亡人数中约有18.2%归因于乳腺癌。每年,估计有10,000多名初期乳腺癌患者在印度被诊断出。目的:评估Ki67在浸润性乳腺癌患者中作为预测性生物标志物的作用,并研究其与乳腺癌各种分子亚型的相关性。 :从印度斯瓦米拉玛·喜马拉雅大学喜马拉雅医学研究所喜马拉雅医学科学研究所病理学科获得的100例乳腺癌的横断面和描述性研究,历时一年,从2013年至2014年。患者随机选择进行研究。结果:69例患者的Ki67增殖指数高(> 30%),其次是20%的患者低增殖指数(≤15%)和11%的患者中等增生指数(16-30%)。最多的患者属于Luminal A亚型,其中50%显示高增殖指数。在Luminal B亚型中,有64%的患者表现出高增殖指数,而在Her-2亚型中,有73.9%的患者表现出高增殖指数。在三阴性乳腺癌(TNBC)中,有86.3%的亚型显示出高增殖指数。大多数患者为IDC(n = 94)。在这些患者中,有64名(68%)患者显示出Ki67免疫染色的高增殖指数。在5例ILC患者中,有3例(60%)显示出Ki67免疫染色的高增殖指数。 1例黏液癌的Ki67免疫染色增殖指数低。结论:高增殖指数的肿瘤多数较大。我们找不到与乳腺癌的各种分子亚型有任何相关性。尽管没有统计学意义,但我们观察到TNBC具有最强的侵袭性,并显示出最高的增殖和Ki67表达率。高水平的Ki67与TNBC,Her2 / neu和Luminal B相关,而中低水平与Luminal A亚型相关。 Ki67免疫染色可以用作增殖的重要生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号